 |
BioWorld-International-2004-04-28
Antisoma's Stock Falls On Phase III Miss With R1549
Antisoma's Stock Falls On Phase III Miss With R1549
LONDON - Antisoma plc's share price was halved Monday after the company announced its lead product, R1549, failed in a Phase III ovarian cancer trial -survival of R1549-treated patients was no better than patients in the comparative arm. (BioWorld International)